British American Tobacco (BATS) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
8 Jan, 2026Executive summary
2024 results were in line with expectations, driven by transformation initiatives, robust growth in AME and APMEA, and recovery in U.S. Combustibles.
Smokeless products now account for 17.5% of group revenue, with 3.6 million new consumers added, reaching 29.1 million.
Shareholder returns prioritized through improved financial flexibility, 2% dividend growth, and a £900m share buyback planned for 2025.
Leverage reduced to 2.4x, with strong cash returns and a focus on sustainable transformation.
Confident in sustainable transformation, with 2025 as a deployment year and a return to mid-term growth algorithm in 2026.
Financial highlights
Organic, constant currency group revenue grew 1.3% year-over-year; new category revenue up 8.9%; adjusted operating profit rose 1.4%; diluted EPS increased 3.6%.
Adjusted gross profit expanded by GBP 400 million, with gross margin up 60bps to 67.2%.
Excluding the U.S., revenue grew 5.1% and operating profit 7.5%.
Modern Oral revenue surged 53%, with category share up 130 basis points.
Operating cash conversion exceeded 100% for the fifth consecutive year.
Outlook and guidance
2025 guidance: group revenue growth around 1%, APFO growth of 1.5%-2.5% (adjusted for Canada), with significant headwinds in Bangladesh and Australia.
2026 targets: 3%-5% revenue growth and 4%-6% APFO growth, adjusted for Canada at constant rates.
Performance expected to be second-half weighted in 2025 due to new category innovation rollouts.
Continued focus on U.S. performance improvement, Velo growth, innovation deployment, and strong AME delivery.
Latest events from British American Tobacco
- Accelerating smokeless transformation and U.S. growth through innovation and regulatory action.BATS
Consumer Analyst Group of New York Conference (CAGNY) 202619 Feb 2026 - 2025 results hit top guidance, led by Modern Oral growth and strong U.S. and AME performance.BATS
H2 202512 Feb 2026 - New Category growth and innovation offset U.S. headwinds, supporting full-year guidance.BATS
H1 20243 Feb 2026 - Guidance reaffirmed as new categories and innovation drive H2 acceleration and cash returns.BATS
Trading Update31 Jan 2026 - Accelerating innovation and smokeless growth, with robust financials and U.S. market stabilization.BATS
21st Annual dbAccess Global Consumer Conference 202431 Jan 2026 - Accelerates smokeless transformation, targeting >50% revenue from new categories by 2035.BATS
CMD 202419 Jan 2026 - On track for guidance with innovation, new category growth, and strong cash generation.BATS
Trading Update11 Jan 2026 - FY25 outlook reaffirmed with growth, strong U.S. momentum, and a £1.3bn FY26 share buy-back.BATS
Trading Update9 Dec 2025 - FY25 outlook raised as U.S. and Modern Oral growth offset regulatory headwinds.BATS
Trading Update18 Nov 2025